EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> Lundbeck offloaded two preclinical programs to AstraZeneca. The deal continues Lundbeck’s push to shed assets that are outside of its area of focus. Statement

> UniQure presented data on its hemophilia B gene therapy program. The data suggest the vector used by uniQure achieves liver transduction in the presence of pre-existing anti-AAV5 neutralizing antibodies. Release 

> 4D Pharma gained clearance to trial a commensal bacteria strain in cancer patients. The trial will look at the immunomodulatory effects of MRx0518 in people with solid tumors. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sensorion raised €8.7 million ($10.2 million). The money will fund the completion of a phase 2 trial of SENS-111 in patients with rare ear disease vestibular neuritis. Release 

> Cellectis gained clearance to increase the dose levels in a phase 1 trial of off-the-shelf CAR-T drug UCART123. The French biotech is also opening another site in a bid to increase the speed of enrollment. Statement 

Suggested Articles

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial.